The Manila Times

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical ...
Tech Times

Quantum Computing: Unlocking Qubits Science, Tech Breakthroughs, and Future Applications

Understanding quantum computing, from qubits science and tech breakthroughs to future quantum applications, and discovering how close we are to real-world use cases ...

MKS Inc. (MKSI) Presents at 53rd Annual Nasdaq Investor Conference Transcript

MKS Inc. (MKSI) 53rd Annual Nasdaq Investor Conference December 9, 2025 6:00 AM ESTCompany ParticipantsJohn Lee - President, CEO & ...